Trial Profile
ASP3550 Phase II Study - A Maintenance-Dose-Finding Study of Three-Month Depot in Patients With Prostate Cancer -
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 19 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Dec 2010 New trial record